Asymchem Group

The Asymchem team is headed to ACS Fall 2024! We're eager to connect with the chemistry community, share insights,and explore new possibilities. Looking forward to productive conversations in Denver! . #ACSFall2024 #chemistry #pharma

In the production of active pharmaceutical ingredients (APIs), high pressure chemistry is frequently utilized, particularly in reactions that use gas as a reagent, like catalytic hydrogenation. At Asymchem, we have invested substantial effort in forming a specialized research team and enhancing our capabilities at our facilities to support this essential HPP technology. Our 300-3000L autoclaves are constructed from stainless steel and Hastelloy, with pressure ratings between 4 and 9 MPa. . #complexchemistry #cdmoSolutions #APIs . 📖 https://okt.to/nQD0Po

Asymchem offers integrated solutions spanning the entire drug substance and drug product life cycle, backed by cutting-edge technology including flow chemistry and green manufacturing. . We are well-versed in the #CDMO landscape and are eager to your upcoming project. Join us at #CPHIWorldwide in Milan, Italy, and visit us at booth 7D2! . #biotech #pharma #chemistry

Join us July 30th at 10am ET! Our own, Charles Chase will be diving into a conversation titled, "Fragment-Based Oligonucleotide and Oligopeptide Synthesis." 🔗 to register: https://okt.to/6jLgh8 . Advancements towards fragment-based approaches for oligonucleotide and oligopeptide synthesis will be presented. Leveraging Asymchem's expertise in synthetic chemistry, continuous processing, and enzyme engineering/biotransformation, we have developed an innovative liquid/solid phase hybrid synthesis platform using oligomer-fragments to manufacture complex oligonucleotides and peptides. Advantages, scope and limitations of fragment-based manufacturing methods, and the comparison to traditional solid-phase or liquid synthesis approaches, will be presented. . #oligonucleotide #peptides

We understand the CDMO landscape and want to walk with you through your next project. We're heading to #CPHIWorldwide in Milan, Italy and hope to see you there at 𝗯𝗼𝗼𝘁𝗵 𝟳𝗗𝟮! Asymchem is a comprehensive contract development and manufacturing organization (CDMO) with a complete continuum of support from preclinical to commercialization. Founded in 1997, Asymchem offers integrated solutions spanning the entire drug substance and drug product life cycle, backed by cutting-edge technology including flow chemistry and green manufacturing. With R&D and manufacturing operations in China, Europe, and the U.S. and a team of proven experts, we provide a full range of CDMO services for a global client base. #cdmo #cphimilan #chemistry

From the beginning of your work with us, we strive to be your full-service peptide supplier, connecting every step in your journey to bring your molecule to market. Our dedicated analytical team can provide structure characterization, analytical method development, validation, IPC support, final product release testing, and stability study according to ICH requirements. In addition, our peptide experts provide document preparation service to support IND/NDA filing. Utilizing QbD processes, analytical design, and technical transfer via scale-down model (SDM), we support process validation and NDA filing. Technology Enabling Superior Peptide Supply: ✔️ Solid/liquid phase preparation ✔️ Chromatography separation ✔️ Membrane concentration/purification ✔️ Lyophilization and spray drying ✔️ Flow chemistry and biotransformation platform for complex key materials production #peptides #asymchem #CDMOSolutions

Discover our cutting-edge Highly Potent Active Pharmaceutical Ingredients (HPAPIs or HPAIs) compounds that are revolutionizing the industry. 🌟 Designed with precision, our facilities prioritize safety by implementing both GMP and non-GMP configurations. From common potent compound classes to specialized equipment, we've thoughtfully crafted every element to minimize risk and contamination. 🔗 https://okt.to/EJC73h

Explore the capabilities💡 of our Chemical Macromolecule Division (CMMD) to enhance a variety of peptide-based molecules, including complex structures like peptide-drug conjugates. Our skilled analytical team 👩🔬 offers comprehensive support for structure characterization, method development, quality control testing, and adherence to regulatory guidelines like ICH. Benefit from expert assistance in documentation for IND/NDA submissions. Leveraging QbD methods and SDM for process validation and regulatory approval. #peptides #CDMOSolutions View more info in detail👇 📖 https://okt.to/NIQDC1

We are excited to announce that Dr. Cheng Yi Chen has joined the Asymchem team as our Small-Molecule Sector CTO. Dr. Chen Yi Chen brings extensive experience in small molecule API manufacturing, quality, and compliance. Please join us in welcoming him! 🔗 https://okt.to/bDev5s #smallmolecule #CDMO

High Potency APIs Market Market worth $39.6 billion by 2027 Download PDF Brochure for More Details@ https://lnkd.in/dehXfZur The global High Potency APIs Market is projected to reach USD 39.6 billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The growth in this market is driven by factors such as increasing demand for #oncology drugs, growing demand for #antibodydrug conjugates, increasing focus of leading #pharmaceuticalcompanies on HPAPIs, advancements in #HPAPI #manufacturing technologies, and growing focus on precision Key Players: Lonza Polpharma API CARBOGEN AMCIS Sterling Pharma Solutions Ajinomoto Bio-Pharma Services Axplora (formerly Novasep-PharmaZell) Nanoform Flamma Group Cerbios-Pharma SA Evonik Eurofins CDMO FAREVA AMBOISE Porton Pharma Solutions Ltd. Cambrex Alcami Corporation WuXi AppTec Recipharm Corden Pharma - A Full-Service CDMO SEQENS Piramal Pharma Solutions Alcami Corporation Syngene International Limited Samsung Biologics Laurus Labs Limited Hovione Pharmaron MINAKEM Asymchem Group